At a glance
ClinicalIndex Comparison RecordN/ACompleted· 70 enrolled
Drug / intervention
Stereotactic body radiotherapy +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
In Brief
A clinical study evaluating Stereotactic body radiotherapy and Research blood draw for Sarcoma and 3 related conditions. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This is a study evaluating the safety and efficacy of Lattice SBRT for patients with large tumors (≥ 4.5 cm) planning to undergo palliative radiotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
CountriesUnited States
CollaboratorsGoldman Sachs Foundation (Emerson Collective)
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartSep 2020
Primary CompletionSep 2022
Study CompletionMay 2023
TodayJul 2026
First PostedSep 17, 2020
Enrollment StartSep 22, 2020
Primary CompletionSep 30, 2022
Study CompletionMay 4, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.8 years ago
Interventions
Stereotactic body radiotherapyradiation
Treatment will take approximately 2 weeks.
Research blood drawprocedure
-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up